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A B S T R A C T
The objective of this study was to develop a stable spray dried formulation, containing the three serotypes of
Sabin inactivated polio vaccine (sIPV), aiming for minimal loss of native conformation (D-antigen) during drying
and subsequent storage. The inﬂuence of atomization and drying stress during spray drying on trivalent sIPV was
investigated. This was followed by excipient screening, in which monovalent sIPV was formulated and spray
dried. Excipient combinations and concentrations were tailored to maximize both the antigen recovery of re-
spective sIPV serotypes after spray drying and storage (T=40 °C and t= 7 days). Furthermore, a fractional
factorial design was developed around the most promising formulations to elucidate the contribution of each
excipient in stabilizing D-antigen during drying. Serotype 1 and 2 could be dried with 98% and 97% recovery,
respectively. When subsequently stored at 40 °C for 7 days, the D-antigenicity of serotype 1 was fully retained.
For serotype 2 the D-antigenicity dropped to 71%. Serotype 3 was more challenging to stabilize and a recovery of
56% was attained after drying, followed by a further loss of 37% after storage at 40 °C for 7 days. Further studies
using a design of experiments approach demonstrated that trehalose/monosodium glutamate and maltodextrin/
arginine combinations were crucial for stabilizing serotype 1 and 2, respectively. For sIPV serotype 3, the best
formulation contained Medium199, glutathione and maltodextrin. For the trivalent vaccine it is therefore
probably necessary to spray dry the diﬀerent serotypes separately and mix the dry powders afterwards to obtain
the trivalent vaccine.
1. Introduction
Poliomyelitis is a highly infectious disease, caused by at least one of
the three serotypes of poliovirus, the disease can be prevented through
vaccination. Live attenuated oral polio vaccine (OPV, based on Sabin
strains) is widely used because of its eﬀectiveness, low cost and ease of
administration. However, a major concern with the use of OPV is
generation of vaccine-derived poliovirus by reversion of the attenuated
OPV, causing rare vaccine associated paralytic poliomyelitis (VAPP)
[1–3]. Inactivated polio vaccine (IPV, based on wild type Salk strains) is
safe, but much more expensive because the puriﬁcation requires more
unit operations (e.g. chromatography) and the vaccine dose needs to be
higher due to the inability of the inactivated vaccine particles to re-
plicate after administration.
To achieve global eradication of polio (both wild-type polio viruses
as well as vaccine-derived viruses), the Global Polio Eradication
Initiative (GPEI) has deﬁned an endgame strategy. This includes a
phased withdrawal of OPV and global inclusion of IPV into all routine
vaccination programs [4]. Besides the changes in the existing im-
munization programs, more aﬀordable, eﬃcacious and safely manu-
factured polio vaccines are required. The GPEI is pursuing initiatives to
minimize IPV costs for developing countries by introducing low-cost
IPV based on Sabin strains, instead of Salk strains [5,6].
A drawback of both OPV and IPV, which are marketed as liquid
vaccines, is the requirement of a cold chain for their transport and
storage. Maintenance of the cold chain is challenging, especially in
developing countries, where these vaccines are needed the most [7].
For use in emergency vaccination and post-eradication stockpiling, a
thermally stable formulation is strongly desired to maintain vaccine
potency during storage and transport.
A potential strategy to stabilize vaccines is to dry them in the pre-
sence of stabilizing excipients. Removal of water and incorporation of
excipients can improve the stability of vaccines due to decreased mo-
bility and prevention of degradation pathways that are facilitated by
water [8,9]. A previous study by Kraan et al. [10] showed that freeze-
drying is suitable to stabilize traditional Salk IPV, producing a
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thermostable vaccine in form of dried cakes. Spray drying may be an
attractive alternative for freeze-drying because spray dried powder may
provide opportunities for new vaccine delivery routes (especially pul-
monary and mucosal routes) [11–15]. However, careful selection of the
formulation matrix (sugars, polymers, amino acids and surfactants) is
required to spray dry labile vaccines in order to retain their potency
during and after spray drying [16]. Potency correlates with the pre-
sence of D-antigen. Only D-antigen induces poliovirus neutralizing an-
tibodies. Under stress conditions the particle loses D-antigen epitopes
and, as a result, its ability to induce functional antibodies.
In this study, we describe the search for a formulation of a dry sIPV
produced by spray drying. This was done by (i) studying the inﬂuence
of process stress elements on sIPV, (ii) an excipient screening aiming to
minimize the loss of sIPV D-antigenicity upon drying (and subsequent
reconstitution), and (iii) investigating the eﬀects of various excipients
on the thermostability of dry sIPV. Furthermore, a fractional factorial
design was developed around the most promising formulations to elu-
cidate the contribution of each excipient in stabilizing D-antigen.
2. Materials and methods
2.1. Vaccine
Monovalent Sabin IPV bulk material used in this study was pro-
duced as described previously [17]. The monovalent IPV bulk con-
centration was 476, 382 and 323 D-antigen units (DU) per mL for type
1, type 2 and type 3, respectively. D-antigen is the native conforma-
tional state of the polio virus particle. Only virus and vaccine with D-
antigenicity is able to induce virus neutralizing antibodies.
2.2. Excipients
The excipients D-trehalose dihydrate, sodium citrate dihydrate, L-
arginine, dextrin (maltodextrin) from maize starch (10) were purchased
from Sigma (USA). Magnesium chloride hexahydrate and L-glutamic
monosodium salt monohydrate (MSG) were from Merck (Germany),
Medium199 from Bilthoven Biologicals (The Netherlands), Pluronic® F-
68 and PBS (0.01M, pH 7.2) from Gibco life technology (USA).
2.3. Dialysis
Unless otherwise indicated, the monovalent IPV bulk material was
dialyzed against PBS (0.01M, pH 7.2) using a 10 kDa molecular weight
cut-oﬀ, low binding regenerated cellulose membrane dialysis cassette
(Slide-A-Lyzer®, Pierce, Thermo Scientiﬁc, USA) to replace the buﬀer
components of the sIPV bulk (M199 medium). PBS has earlier [18,19]
been shown to be a suitable buﬀer for spray drying of inactivated viral
vaccines.
2.4. Formulation preparation
For spray drying trivalent sIPV, all excipients were dissolved in PBS
and pH was adjusted to 6.8. In case of spray drying with monovalent
sIPV, excipients were also dissolved in PBS and pH was adjusted to 6.8
for type 1 and 2 and pH 6.4 for type 3. The dialyzed sIPV (monovalent
or trivalent) was added to the liquid formulation to a ﬁnal concentra-
tion of 10, 16 and 32 DU for type 1, type 2, and type 3 respectively
before drying. PH settings were based on prior studies (data not
shown).
2.5. Spray drying process
Sabin IPV powders were produced using a Büchi mini spray-drier B-
290 in conjunction with a high performance cyclone and a B-296 de-
humidiﬁer (both from Büchi Labortechnik AG). All the experiments
were performed in a closed loop conﬁguration using nitrogen as drying
medium. A two-way nozzle with oriﬁce diameter of 0.7mm was used in
a co-current mode. The nitrogen pressure was set constant at 5 bar. The
spray drying parameters were ﬁxed after initial optimization. These
ﬁxed settings were as follows: inlet air temperature 110 °C; feed ﬂow
rate 3.1mL/min; atomizing airﬂow 12.4 L/min (corresponding to an
equipment setting of 40mm); and an aspirator rate of 22 m3 n/h; this
corresponded to an instrument setting of 100%.
After spray drying the spray dried product was collected and ali-
quoted (100mg) in vials (3 mL vial, Nuova Ompi) in a glove box (Terra
Universal Inc, Series 100) under a relative humidity< 3% as measured
by relative humidity analyzer [20]. The vials were subsequently sealed.
2.6. D-antigen ELISA
The D-antigen ELISA was performed as described by Westdijk et al.
[21]. Polystyrene 96-well plates (Greiner, Austria) were coated over-
night at room temperature with bovine anti-polio serum (Bilthoven
Biologicals, The Netherlands) and blocked with 1% BSA (Sigma–Al-
drich) for 30min at 37 °C. The plates were washed 3 times with PBS
(0.01M) containing 0.05% Tween 80 (Merck, Germany). A series of
eight twofold dilutions of IPV-formulation (in triplicate) in 0.01M PBS
containing 0.05% Tween 80 was added to each plate and incubated at
37 °C for 2 h. The unbound antigen was then removed and the plates
were washed as above. Type-speciﬁc monoclonal antibodies [mAb
Hyb295-17-02 (type 1, Thermo scientiﬁc), Hyb294-06-02 (type 2,
Thermo scientiﬁc) and 4-8-7 (type 3, Bilthoven Biologics)] were added
and the plates were incubated at 37 °C for 2 h. For trivalent sIPV ex-
cipient screening, Hyb300-05-02 (type3, Thermo scientiﬁc) was used.
After washing the plate, HRPO-conjugated goat anti-mouse IgG
(Southern Biotech) was added to each well, followed by incubation at
37 °C for 2 h. Plates were then washed and tetramethylbenzidine (TMB)
substrate (Sigma–Aldrich) was added. After 10min the reaction was
stopped by addition of 0.2 M H2SO4 and absorbance at 450 nm was
measured with Synergy Mx plate reader (BioTek, USA). Assay data were
analyzed by four-parameter logistic curve ﬁtting with Gen5 software.
D-antigen units were calculated relative to the reference standard.
Unless stated otherwise, D-antigen recovery values were calculated by
using the liquid formulations prior to spray drying as the 100%-re-
ference.
2.7. Residual moisture content (RMC)
The RMC of spray dried sIPV vaccine samples was determined using
a C30 Compact Karl Fischer Coulometer (Mettler-Toledo). Samples of
approximately 100mg dried powder vaccine were reconstituted in 1mL
HYDRANAL Coulomat A (Sigma-Aldrich) and subsequently 100 µL was
injected into the titration vessel. Each sample was measured in tripli-
cate. The relative moisture content was calculated using a reference
curve of H2O in Coulomat A, the weight of the dried product in the vial,
the ratio between the volume for reconstitution (1 mL) and injection
into the titration vessel (100 µL).
2.8. Geometric particle size
The geometric particle size (X50 deﬁned as the median particle size)
of the spray dried powder products was analyzed on the following day
(24 h) after spray drying by laser diﬀraction with a Helos system
(Sympatec GmbH). The powder was dispersed into the Helos system
using an aspiros dispersing system operated at a dispersing pressure of
1.0 bar. The vaccine powder was measured with a lens having a mea-
suring range of 0.1/0.18–35mm. Furthermore, to check for any ag-
gregates the analysis was repeated by increasing the dispersing pres-
sure. Increasing the dispersion pressure up to 5.0 bar did not result in a
change of the measured particle size distribution, which indicated that
the size distribution of the primary particles was obtained upon per-
forming the analysis at 1.0 bar. Results are the mean of three
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independent measurements.
2.9. Design of experiments (DoE)
The DoE model was prepared and evaluated using MODDE 12.0
software (Umetrics, Sartorius). Models were ﬁtted with multiple linear
regression (MLR) and adjusted by removing non-signiﬁcant model
terms. The screening experiment for trivalent sIPV used a full factorial
design, consisting of 19 experimental runs. For studies requiring in-
vestigation of relative contribution of excipients to monovalent ser-
otypes, a fractional factorial design was used, consisting of in total 11
experimental runs. The choice of a fractional factorial design instead of
a full factorial design (requires 19 runs) was made because of eﬃciency
as fewer experimental runs would give the same amount of information
and will require less sIPV. To reduce systematic errors, all the experi-
ments were randomized.
3. Results and discussion
3.1. Impact of shear stress during spray drying on trivalent sIPV activity
The impact of atomization shear stress, on the D-antigenicity of the
trivalent IPV was investigated. Shear stress may occur when the vaccine
and excipient containing liquid is atomized into small droplets, which
may reduce antigen activity. To understand the impact of shear stress in
our settings, the nozzle was taken out of the drying system and trivalent
sIPV containing 10/16/32 DU of serotype 1, 2 and 3 respectively, was
atomized at 12.4 L/min and a pump speed of 3.1 mL/min. This setup
excluded any eﬀect of heating as for this experiment the nozzle was
placed outside the heating chamber. The generated aerosols were col-
lected and analyzed for the loss in DU compared to the starting bulk.
The D-antigen recovery was≥90% for all serotypes and the conﬁdence
intervals also included a full D-antigen recovery (see Fig. 1) indicating
only a minor D-ag loss (< 10%) due to atomization. In a previous study
on viral vectors based on adenovirus [22], an increase in atomization
pressure (7.3 L/min to 11.2 L/min) increased the loss in viral in-
fectivity. In this study, however, no negative eﬀect of the atomization
on the D-antigen recovery of the viral vaccine was detected. Conse-
quently, an atomization rate of 12.4 L/min and pump speed of 3.1 mL/
min were selected for further experiments.
3.2. Impact of dehydration stress during spray drying on trivalent sIPV
To investigate the inﬂuence of dehydration stress on sIPV D-antigen,
a base formulation was selected, consisting of two components, the non-
reducing disaccharide trehalose (10% w/v) and magnesium chloride
hexahydrate (3% w/v). The pH of the formulation was adjusted to 6.8.
The trivalent sIPV vaccine (10/16/32 DU for type 1, 2 and 3 respec-
tively) in the base formulation was spray dried at three diﬀerent drying
temperatures and feed ﬂow rates (Fig. 2). The D-antigen recovery of
sIPV was aﬀected only to a limited extent within the three tested pro-
cess conditions. However, the diﬀerences between the recovery of the
various serotypes was substantial (Fig. 2). In contrast to atomization,
dehydration resulted in substantial D-antigen decrease of sIPV. As a
result, dehydration was identiﬁed as the main cause for a loss in D-
antigenicity during spray drying. Serotype 1 was least aﬀected by
drying, followed by serotype 3 and 2. Considering the above observa-
tions and the objective to attain maximum D-antigen recovery and low
residual moisture content, an atomization rate of 12.4 L/min, pump
speed of 3.1 mL/min and an inlet drying temperature of 110 °C was
selected for all further studies. It is important to keep the outlet tem-
perature of the process below 55 °C because above that temperature the
native D-antigen conformation of the vaccine changes to the non-native
C-antigenic conformation. Thus, to keep this risk at minimum we
choose the temperature conditions (inlet temperature 110 °C) and thus
outlet temperatures varying between (48–53 °C).
3.3. Excipient screening for spray drying trivalent sIPV
To obtain a sIPV formulation with an improved antigenic recovery
during spray drying, excipient screening using a DoE approach was
performed. The preceding base formulation was selected along with
monosodium glutamate and mannitol based on ﬁndings from the lit-
erature [10]. A full factorial design (Table 1) was performed around the
excipients. In general, the addition of monosodium glutamate (EXP 8,
Table 1) and mannitol (EXP 12, Table 1) did not further improve the D-
antigen recovery during drying compared to the base formulation (EXP
6, Table 1). Serotype 1 in the formulations was least aﬀected during
spray drying, with the best recovery of 46%, followed by 17% for ser-
otype 2 and 22% for serotype 3.
The residual moisture content varied between 2 and 13%. The
powder particle size varied between 3.6 and 6.1 µm, with formulation
containing trivalent vaccine and seemed to be an eﬀect of changing
excipient concentration. Increasing the dispersion pressure from 1 to 5
bars during particle size analysis, did not result in decreased powder
particle size. Thus, it can be assumed that the vaccine powder was not
aggregated during the initial storage. When designing the powder for a
particular route of administration (for example alveolar deposition via
the pulmonary route requires particle size b/w 1–5 µm), additional
optimization may be required.
Overall, D-antigen recoveries were low for all serotypes. Screening
of diﬀerent excipient combinations during sIPV spray drying indicated
a dependency between formulation composition and process loss.
Moreover, the D-antigen recovery data indicates that each serotype was
aﬀected diﬀerently by the same formulation. For that reason, it was
decided to formulate each individual serotype. Thus, further experi-
ments were carried out with monovalent serotypes which were dried
using the same ﬁxed spray drying conditions.
3.4. Stabilizing monovalent Sabin IPV serotypes
Stabilizing formulations were diﬀerent mixtures, containing one or
more of the following components: (i) a non-reducing disaccharide
(trehalose), (ii) a polysaccharide (maltodextrin), (iii) divalent metal ion
(Mg2+), (iv) amino acids (monosodium glutamate, L-arginine, L-glu-
tathione and glycine), (v) sodium salt of an organic acid (citrate), (vi)
cell culture medium (M199) and (vii) a surfactant (Pluronic®). The
Fig. 1. Eﬀect of atomization stress on the D-antigen recovery (%) during spray
drying of trivalent sIPV vaccine. The investigated setting for nozzle shear stress
was 12.4 L/min and the feed ﬂow rate was 3.1 mL/min. Average values± σn−1
(n=3) are depicted.
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spray drying solution consisted of a concentration of 10/16/32 D-an-
tigen units for monovalent serotype 1/2/3, respectively. D-antigen re-
covery after drying and after 1 week storage at 40 °C were determined.
In general, spray drying transformed all the liquid formulations
(described in Table 2) into ﬁne powders with a particle size of 5–7 µm
(Suppl. Table 1). The D-antigen recovery data in Table 3 indicate an
acceptable process related loss in D-antigenicity of 2% for serotype 1
and 21% for serotype 2. However, the loss after spray drying was
considerably higher (44%) for sIPV serotype 3. The formulation com-
position aﬀected both the residual moisture content in the spray dried
powders and the process loss. The RMC of the powders varied between
1 and 7% (Table 3). However, there was no apparent correlation be-
tween either process loss or storage stability and RMC in the observed
range of RMC. The high RMC for dried sIPV formulations could par-
tially be explained by the presence of MgCl2, which is likely present in
the crystalline hexahydrate form. Omitting MgCl2 from the formulation
and ﬁne tuning of the drying process, could decrease the RMC to a level
recommended for dried biologicals by European Pharmacopoeia
(< 3%).
Each monovalent serotype required a speciﬁc formulation compo-
sition amenable for spray drying to reach its maximum D-antigenicity.
For serotype 1 both trehalose 20% (w/v) and maltodextrin 20% (w/v)
performed as good bulking agents, attaining a maximum D-antigen
recovery of 97% and 98% respectively (EXP S1 and S4, Table 3). While
for stabilizing sIPV serotype 2, maltodextrin in combination with L-
arginine 4% (w/v) appeared to be favorable as indicated by the D-
Fig. 2. Eﬀect of spray drying conditions on the D-antigen recovery of trivalent sIPV vaccine. The atomization rate was kept constant for all runs (12.4 L/min).
Average values± σn−1 (n=3) are depicted.
Table 1
Excipient screening for spray drying of trivalent sIPV. The eﬀect of spray drying various formulations on the D-antigen recovery of sIPV type 1, 2, and 3 is shown. Also
included are the residual moisture content (RMC, %) and geometric particle size (X50, µm) of the spray dried, average values (n= 3) are given. The symbol *):
Insuﬃcient powder (powder yield<10%) for analysis, due to sticking in the drying chamber.
Component (w/v, %) D-antigen recovery (%) RMC Particle size X50
EXP Trehalose MSG MgCl2 Mannitol Serotype 1 Serotype 2 Serotype 3 (%) (µm)
1 5 0 0 0 22 5 16 2.7 ± 0.0 3.7 ± 0.1
2 10 0 0 0 25 4 16 3.2 ± 0.1 4.0 ± 0.1
3 5 3 0 0 18 5 16 2.9 ± 0.1 3.6 ± 0.2
4 10 3 0 0 20 10 17 2.2 ± 0.2 4.1 ± 0.2
5 5 0 3 0 38 6 20 13.0 ± 0.1 3.9 ± 0.1
6 10 0 3 0 46 17 22 6.2 ± 0.1 3.9 ± 0.1
7 5 3 3 0 45 11 20 2.7 ± 0.2 5.0 ± 0.3
8 10 3 3 0 44 12 22 4.6 ± 0.1 4.9 ± 0.5
9 5 0 0 5 –* – – – –
10 10 0 0 5 – – – – –
11 5 3 0 5 – – – – –
12 10 3 0 5 40 5 12 1.5 ± 0.3 6.1 ± 0.1
13 5 0 3 5 25 6 14 4.3 ± 0.3 4.9 ± 0.1
14 10 0 3 5 4 0 0 3.8 ± 0.2 5.1 ± 0.3
15 5 3 3 5 18 0 12 3.3 ± 0.3 4.9 ± 0.4
16 10 3 3 5 19 0 10 2.6 ± 0.1 5.1 ± 0.2
17 7.5 1.5 1.5 2.5 21 5 8 2.5 ± 0.1 4.0 ± 0.0
18 7.5 1.5 1.5 2.5 18 2 7 2.8 ± 0.1 4.0 ± 0.1
19 7.5 1.5 1.5 2.5 20 2 4 2.2 ± 0.1 4.1 ± 0.1
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antigen recovery of 79% (EXP S6, Table 3). Trehalose and maltodextrin
probably exert their protective mechanism by immobilization of vac-
cine in an amorphous matrix portrayed by the vitriﬁcation theory [23].
Trehalose has been proven to stabilize both attenuated and inactivated
viral vaccines during spray drying including measles [24], inﬂuenza
[18,25] and human papilloma virus [26]. While, maltodextrin has also
been previously used to stabilize Salk IPV in a formulation used for
vacuum drying recovering roughly half of the starting D-antigen con-
centration [27]. However, it is important to note that Salk strains of IPV
are diﬀerent from Sabin IPV in respect to isoelectric points [28] and
capsid structure (amino acid sequence) that may aﬀect its stability
during drying.
Inclusion of the surfactant Pluronic F68, did not contribute to the D-
antigen recovery of serotype 2, however, it did improve the D-antigen
recovery of serotype 1 by 24% (EXP S5 vs EXP S6, Table 3). Serotype 3
required a formulation containing cell culture medium (M199), which
is a complex medium with approximately 60 components in various
concentrations including amino acids (0.004–0.002% w/v), vitamins
(0.00001–0.000001% w/v) and inorganic salts (0.8–0.0007% w/v).
Table 3 shows type 3 D-antigen recoveries between 40 and 60% (EXP
S7-S9).
The thermal instability of liquid sIPV was clearly evident as the D-
antigenicity of all three unformulated monovalent liquid serotypes in
PBS was undetectable, when stored at 40 °C for 1 week (Liquid,
Table 3). However, serotype 1 formulated in the lead formulations S1
and S4 showed no loss in antigenicity during incubation at 40 °C,
maintaining 97% and 98% DU recovery. A decrease of 18% in
antigenicity was observed for serotype 2 lead formulation S5. It was
interesting to note that the antigenicity of serotype 2 in the S3 for-
mulation had decreased to 52% during drying, but decreased further by
only 13% during storage. This was better than observed for the lead
formulation S5. The strongest decrease in antigenicity after storage was
observed for serotype 3, where a decrease of 37% in DU from its initial
value was observed for lead formulation S8.
3.5. Elucidating the relative contribution of stabilizing excipients
Based on the results of our study so far, the most promising for-
mulations were selected for further investigation to get more insight
into the impact of excipients on the stabilization of sIPV using a DoE
approach. Moreover, according to ICH Q8 guidelines for pharmaceu-
tical development, only the excipients whose use could be justiﬁed
should be included in a formulation [29]. Thus to narrow down the
excipients that contribute to the D-antigen recovery and/or stability, a
design of experiment approach was used. Therefore, a fractional fac-
torial design was developed around the lead formulations S1 (for ser-
otype 1, Fig. 3A), S5 (for serotype 2, Fig. 4A) and S8 (serotype 3,
Fig. 5A). The formulations were spray dried and subsequently stored for
1 week at 40 °C and analyzed to assess the changes in D-antigen re-
covery during storage. The recovery (both after drying and storage) was
calculated in reference to the liquid vaccine control.
Multiple linear regression (MLR) models were ﬁtted to the D-an-
tigen recovery data for sIPV serotype 1 2 and 3, which resulted in valid
models (serotype 1: R2= 0.89, Q2=0.95; serotype2: R2= 0.77,
Table 2
Composition of evaluated formulations for spray drying. Formulations containing a monovalent sIPV type 1 (S1-S6), 2 (S1-S6), or 3 (S7-S9). A-G (arbitrary letters to
segregate component categories).
Formulation composition
EXP A (w/v) B (w/v) C (w/v) D (w/v) E (w/v) F (v/v) G (w/v)
S1 20% trehalose – 8% MgCl2 8% monosodium glutamate – – 3.87% monosodium citrate
S2 10% trehalose – 8% MgCl2 4% L-arginine – – 3.87% monosodium citrate
S3 10% trehalose – 8% MgCl2 4% L-arginine 0.03% Pluronic – 3.87% monosodium citrate
S4 – 20% maltodextrin 8% MgCl2 8% monosodium glutamate 0.03% Pluronic – –
S5 – 20% maltodextrin 8% MgCl2 4% L-arginine – – 3.87% monosodium citrate
S6 – 20% maltodextrin 8% MgCl2 4% L-arginine 0.03% Pluronic – 3.87% monosodium citrate
S7 – 20% maltodextrin – 8% monosodium glutamate
0.62% L-glutathione
4.5% glycine
– 90% M199 –
S8 – 20% maltodextrin – 0.62% L-glutathione
4.5% glycine
– 90% M199 3.87% monosodium citrate
S9 – 20% maltodextrin 8% MgCl2 8% monosodium glutamate
0.62% L-glutathione
4.5% glycine
– 90% M199 3.87% monosodium citrate
Table 3
Eﬀect of spray drying various formulations (see Table 2 for composition) on the D-antigen recovery of sIPV type 1, 2, and 3. Also included is the residual moisture
content (RMC, %) of the dried powder. The thermal stability was studied by determining the D-antigen recovery after storing the dried powder for 1 week at 40 °C
(calculated in comparison to the starting material before drying). The symbol “–” depicts experiment not performed.
After spray drying (t= 0) After 1 week storage at 40 °C
Type 1 (%) Type 2 (%) Type 3 (%) Type 1 (%) Type 2 (%) Type 3 (%)
EXP Recovery RMC Recovery RMC Recovery RMC Recovery Recovery Recovery
Liquid – – – – – – 0 0 0
S1 97 4.2 ± 0.0 46 5.5 ± 0.0 – – 97 32 –
S2 82 7.8 ± 0.4 55 5.4 ± 0.1 – – 59 28 –
S3 68 7.9 ± 0.4 52 5.1 ± 0.2 – – 68 39 –
S4 98 3.3 ± 0.1 71 4.5 ± 0.4 – – 98 52 –
S5 53 6.6 ± 0.2 78 5.6 ± 0.2 – – 24 60 –
S6 77 4.8 ± 0.1 79 6.0 ± 0.4 – – 45 54 –
S7 – – – – 56 2.8 ± 0.1 – – 5
S8 – – – – 56 1.6 ± 0.1 – – 19
S9 – – – – 42 2.1 ± 0.1 – – 0
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Q2=0.73 and serotype 3: R2= 0.94, Q2= 0.69) to predict D-antigen
recoveries directly after spray drying. R2 indicates the model ﬁt
(Goodness of ﬁt, 1= perfect model) and Q2 the prediction power of the
model (Goodness of prediction, values greater than 0.5 is a good ﬁt).
The eﬀect of diﬀerent excipients (excluding non-signiﬁcant parameters)
on D-antigen recovery for sIPV type 1 2 and 3 after spray drying are
depicted in Figs. 3B, 4B and 5B, respectively. For type 3, the M199 to
maltodextrin ratio was kept constant in the design and other excipients
were varied.
For serotype 1 trehalose and monosodium glutamate positively af-
fect the D-antigen recovery (see Fig. 3B). In the absence of any ex-
cipient, almost no powder could be recovered after spray drying (EXP 1,
Fig. 3A). Both trehalose and monosodium glutamate were able to retain
98% D-antigen for serotype 1 that was further maintained during sto-
rage at elevated temperatures for 1 week (EXP 3, Fig. 3A). Interestingly,
absence of either of these components aﬀects the D-antigen recovery
and absence of both trehalose and monosodium glutamate leads to a
complete loss of D-antigenicity (EXP 6, Fig. 3A). An explanation for this
may be that excluding the matrix solute in the feed aﬀects the ability to
encapsulate the bioactive agent which is required to retain bioactivity
during the drying process and subsequent storage. The coeﬃcient plot
(Fig. 3B) obtained from the model indicate that omitting MgCl2 from
the formulation and optimizing the concentration of trehalose and MSG
could lead to a formulation with a minimum number of excipients and
maximum D-antigen recovery.
A similar stabilizing trend was observed for serotype 2.
Maltodextrin and arginine were important to prevent D-antigen dete-
rioration during spray drying. The combination of maltodextrin and
arginine lead to the highest D-antigen recovery of 97% after drying for
serotype 2 (experiment 6, Fig. 4A). However, on storage a decrease of
26% in antigenicity was detected. Absence of both maltodextrin and
arginine (EXP 3, Fig. 4A) leads to complete loss of antigenicity. The
coeﬃcient plots obtained from the model for serotype 2, indicate that
omitting MgCl2 and optimizing the maltodextrin and arginine con-
centration for obtaining a formulation with minimum number of ex-
cipients and a maximum D-antigen recovery.
The stabilizing potential of L-glutathione for serotype 3, during
spray drying was evident from the coeﬃcient plots (Fig. 5B). Moreover,
the coeﬃcient plots indicated that MSG positively inﬂuenced the D-
antigen recovery. The plots obtained from the model further indicated
toward excluding MgCl2 and optimizing the L-glutathione and MSG
concentration to achieve the optimal D-antigen recovery. Considering
that the maximum recoveries of serotype 3 obtained were moderate
when compared to the other serotypes, the formulation requires further
optimization.
Amino acid like monosodium glutamate (8% w/v) or arginine (4%
Fig. 3. (A) Fractional factorial design used for sIPV type 1. Trehalose (tested range 0–20% w/v), MSG (tested rage 0–8% w/v), Sodium citrate (tested range 0–3.87%
w/v) and MgCl2 (tested range 0–8% w/v). Signs (−) represents no excipient, (+) represents middle concentration and (++) represents maximum concentration of
investigated range. (B) The main excipient eﬀects that contribute to the best ﬁtted model (for sIPV serotype 1) are shown in coeﬃcient plot (D-antigen recovery after
spray drying).
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w/v) positively contributed to the D-antigen recovery of all three ser-
otypes (Figs. 3B, 4B and 5B). Use of arginine has been reported to be
beneﬁcial for spray drying of live attenuated measles virus vaccine
[24]. Moreover, it has been shown to reduce protein–protein interac-
tions, thereby reducing aggregation [30]. This could be the mechanism
through which sIPV is stabilized during spray drying. In addition, L-
glutathione (0.62% w/v) positively contributed to D-antigenic recovery
of serotype 3 during spray drying. The stabilizing eﬀect may be due to
the direct interaction of L-glutathione with the viral capsid [31].
In previous studies, divalent cations like Mg2+ have shown to be
beneﬁcial for liquid live attenuated oral polio vaccine [32]. Chen et al.
[33] described that MgCl2 stabilizes poliovirus conformation by speciﬁc
ion interaction with capsid proteins. Another study from Kraan et al.
[10] investigating freeze-drying of Salk IPV in vials and bioneedles
[34], showed that inclusion of MgCl2 improved the D-antigen recovery
of all three serotypes, especially upon storage after drying. However,
the current study shows that MgCl2 was not beneﬁcial for spray drying
of sIPV. From the three fractional factorial designs investigating the
serotypes 1, 2 and 3 respectively, it may be concluded that MgCl2 was
an unfavorable excipient candidate for stabilization of sIPV during
spray drying and storage. This apparently contrasts with the favorable
eﬀect of Mg2+ on the thermostability of Sabin poliovirus in the liquid
state [33]. Thus, to minimize the complexity of the formulation, mag-
nesium chloride should be excluded from the formulation. In addition,
it was found that every serotype could be reproducibly spray dried with
similar D-antigenic recoveries (EXP 9, 10 and 11, Figs. 3A, 4A and 5A)
indicating robustness of the drying method.
Despite the large number of excipient combinations evaluated in
these studies, it is quite possible that the speciﬁc formulations tested
here did not include the fully optimized composition. Although it was
possible to produce a formulation that had close to 100% recovery after
drying for serotype 1 and 2. For serotype 3, this was more challenging
as here a maximum D-antigen recovery of 56% was found after spray
drying. This might be improved in the future by adding (an) other ex-
cipient(s) to EXP 5, Fig. 5A.
The stability during storage at 40 °C for a week varied for each
serotype, the observed thermostability decreases in the following order:
serotype 1 > serotype 2 > serotype 3. The formulation for serotype 1
[trehalose (20% w/v) and MSG (8% w/v)] could fully retain the D-
antigenicity on storage at 40 °C for 1 week. Serotype 2 containing for-
mulation [maltodextrin (20% w/v) and arginine (8% w/v)] showed a
slight (18%) decrease in D-antigenicity on storage. Serotype 3 exhibited
the most prominent loss in D-antigenicity on storage. It is speculated
that the observed thermal instability of sIPV serotype 3 (formalin in-
activated virus) is an intrinsic characteristic of the type 3 particle, as
this instability (compared to the other two polio serotypes) has also
been observed in studies with live attenuated type 3 Sabin virus [35].
The stability was assessed for a week at 40 °C, aiming for a controlled
temperature chain approach deﬁned by WHO for use of vaccine outside
the cold chain [36]. For an uncontrolled temperature chain extended
stability studies should be performed.
Fig. 4. (A) Fractional factorial design used for sIPV type 2. Maltodextrin (tested range 0–20% w/v), Arginine (tested range 0–4% w/v), Sodium citrate (0–3.87% w/v)
and MgCl2 (0–8% w/v). Signs (−) represents no excipient, (+) represents middle concentration and (++) represents maximum concentration of investigated range.
(B) The main excipient eﬀects that contribute to the best ﬁtted model (for sIPV serotype 2) are shown in coeﬃcient plot (D-antigen recovery after spray drying).
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4. Conclusions
This study shows the feasibility and limitations of spray drying sIPV
in a tailored formulation for each respective serotype either 1, 2, or 3.
Although further improvement is still needed for type 3, these ﬁndings
show the possibility to produce a spray dried vaccine powder based on
safer (with respect to production of vaccine virus) sIPV [37], which
could be used for stockpiling and distribution in developing countries
without the need of a cold chain transport. In addition, the dried
powder formulation provides opportunities for vaccine delivery via
alternative routes like the intranasal or sublingual route [38].
Acknowledgements
The authors would like to thank Jeroen Bos for his helpful assistance
with D-antigen Elisa.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.ejpb.2018.05.021.
References
[1] F. Friedrich, Rare adverse events associated with oral poliovirus vaccine in Brazil,
Braz. J. Med. Biol. Res. 30 (6) (1997) 695–703.
[2] O.M. Kew, et al., Vaccine-derived polioviruses and the endgame strategy for global
polio eradication, Annu. Rev. Microbiol. 59 (2005) 587–635.
[3] P. Minor, Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication,
Vaccine 27 (20) (2009) 2649–2652.
[4] Polio Eradication and Endgame Strategic Plan 2013–2018, 2013. Available
from:< http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.
pdf> .
[5] H. Okayasu, et al., Aﬀordable inactivated poliovirus vaccine: strategies and pro-
gress, J. Infect. Dis. 210 (Suppl 1) (2014) S459–S464.
[6] W.A. Bakker, et al., Inactivated polio vaccine development for technology transfer
using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV,
Vaccine 29 (41) (2011) 7188–7196.
[7] D. Chen, D. Kristensen, Opportunities and challenges of developing thermostable
vaccines, Expert Rev. Vaccines 8 (5) (2009) 547–557.
[8] M.J. Maltesen, M. van de Weert, Drying methods for protein pharmaceuticals, Drug
Discov. Today Technol. 5 (2–3) (2008) e81–e88.
[9] M.C. Manning, et al., Stability of protein pharmaceuticals: an update, Pharm. Res.
27 (4) (2010) 544–575.
[10] H. Kraan, et al., Development of thermostable lyophilized inactivated polio vaccine,
Pharm. Res. 31 (10) (2014) 2618–2629.
[11] W.H. Lin, et al., Successful respiratory immunization with dry powder live-atte-
nuated measles virus vaccine in rhesus macaques, Proc. Natl. Acad. Sci. USA 108 (7)
(2011) 2987–2992.
[12] L. Garcia-Contreras, et al., Immunization by a bacterial aerosol, Proc. Natl. Acad.
Sci. USA 105 (12) (2008) 4656–4660.
[13] M. Pastor, et al., Cellulose acetate phthalate microparticles containing Vibrio cho-
lerae: steps toward an oral cholera vaccine, J. Drug Target. 22 (6) (2014) 478–487.
[14] R.P. Gala, et al., Physicochemical and preclinical evaluation of a novel buccal
measles vaccine, AAPS PharmSciTech (2016).
[15] J.P. Amorij, et al., Towards tailored vaccine delivery: needs, challenges and per-
spectives, J. Control. Release 161 (2) (2012) 363–376.
[16] G. Kanojia et al., Developments in the formulation and delivery of spray dried
vaccines, Hum. Vaccin. Immunother. (2017) 0.
[17] Y.E. Thomassen, et al., Improved poliovirus D-antigen yields by application of
diﬀerent Vero cell cultivation methods, Vaccine 32 (24) (2014) 2782–2788.
[18] G. Kanojia, et al., A design of experiment approach to predict product and process
parameters for a spray dried inﬂuenza vaccine, Int. J. Pharm. 511 (2) (2016)
1098–1111.
[19] V. Saluja, et al., A comparison between spray drying and spray freeze drying to
produce an inﬂuenza subunit vaccine powder for inhalation, J. Control. Release 144
(2) (2010) 127–133.
[20] G. Kanojia, et al., The production of a stable inﬂiximab powder: the evaluation of
Fig. 5. (A) Fractional factorial design used for
sIPV type 3. L-glutathione (tested range
0–6.2 mg/mL), Monosodium glutamate (tested
range 0–8% w/v), Sodium citrate (tested range
0–3.87% w/v) and MgCl2 (tested range 0–8%
w/v). The two excipients that were ﬁxed and
included in all the formulations were mal-
todextrin 20% (w/v) and M199-glycine 90%
(v/v). Signs (−) represents no excipient, (+)
represents middle concentration (++) re-
presents maximum concentration of in-
vestigated range. (B) The main excipient ef-
fects that contribute to the best ﬁtted model
(for sIPV serotype 3) are shown in coeﬃcient
plot (D-antigen recovery after spray drying).
G. Kanojia et al. European Journal of Pharmaceutics and Biopharmaceutics 129 (2018) 21–29
28
spray and freeze-drying for production, PLoS One 11 (10) (2016) e0163109.
[21] J. Westdijk, et al., Characterization and standardization of Sabin based inactivated
polio vaccine: proposal for a new antigen unit for inactivated polio vaccines,
Vaccine 29 (18) (2011) 3390–3397.
[22] D.A. LeClair, et al., Evaluation of excipients for enhanced thermal stabilization of a
human type 5 adenoviral vector through spray drying, Int. J. Pharm. 506 (1–2)
(2016) 289–301.
[23] J.H. Crowe, L.M. Crowe, D. Chapman, Preservation of membranes in anhydrobiotic
organisms: the role of trehalose, Science 223 (4637) (1984) 701–703.
[24] S. Ohtake, et al., Heat-stable measles vaccine produced by spray drying, Vaccine 28
(5) (2010) 1275–1284.
[25] P.M. Lovalenti, et al., Stabilization of live attenuated inﬂuenza vaccines by freeze
drying, spray drying, and foam drying, Pharm. Res. (2016).
[26] S. Saboo, et al., Optimized formulation of a thermostable spray-dried virus-like
particle vaccine against human papillomavirus, Mol. Pharm. 13 (5) (2016)
1646–1655.
[27] S.Y. Tzeng, et al., Thermostabilization of inactivated polio vaccine in PLGA-based
microspheres for pulsatile release, J. Control. Release 233 (2016) 101–113.
[28] Y.E. Thomassen, et al., Isoelectric point determination of live polioviruses by ca-
pillary isoelectric focusing with whole column imaging detection, Anal. Chem. 85
(12) (2013) 6089–6094.
[29] I.H.T. Guideline, Pharmaceutical Development Q8(R2) (2008),< http://www.ich.
org/products/guidelines/quality/quality-single/article/pharmaceutical-
development.html> .
[30] T. Arakawa, et al., Biotechnology applications of amino acids in protein puriﬁcation
and formulations, Amino Acids 33 (4) (2007) 587–605.
[31] R. Abdelnabi, L. Delang, J. Neyts, Glutathione is a highly eﬃcient thermostabilizer
of poliovirus Sabin strains, Vaccine 35 (10) (2017) 1370–1372.
[32] J.L. Melnick, Thermostability of poliovirus and measles vaccines, Dev. Biol. Stand.
87 (1996) 155–160.
[33] C.H. Chen, et al., Elucidating mechanisms of thermostabilization of poliovirus by
D2O and MgCl2, Arch. Biochem. Biophys. 342 (1) (1997) 108–116.
[34] H. Kraan, et al., Alternative delivery of a thermostable inactivated polio vaccine,
Vaccine 33 (17) (2015) 2030–2037.
[35] P.A. Pipkin, P.D. Minor, Studies on the loss of infectivity of live type 3 poliovaccine
on storage, Biologicals 26 (1) (1998) 17–23.
[36] C. Steﬀen, et al., A ﬁeld based evaluation of adverse events following MenAfriVac
(®)vaccine delivered in a controlled temperature chain (CTC) approach in Benin,
Pan Afr Med J 18 (2014) 344.
[37] P. Verdijk, et al., Safety and immunogenicity of a primary series of Sabin-IPV with
and without aluminum hydroxide in infants, Vaccine 32 (39) (2014) 4938–4944.
[38] H. Kraan, et al., Alternative administration routes and delivery technologies for
polio vaccines, Expert Rev Vaccines 15 (8) (2016) 1029–1040.
G. Kanojia et al. European Journal of Pharmaceutics and Biopharmaceutics 129 (2018) 21–29
29
